Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian indices continue to slide
Mon, 17 Nov 11:30 am

After opening in the red, the Indian Indices have continued to slide and have remained below the dotted line during the morning trading session. Majority of sectoral indices are witnessing selling pressures, with metal and healthcare stocks being the top losers. However, stocks from consumer durables, auto and power sectors are in demand.

The BSE-Sensex is trading down 99 points. The NSE-Nifty is trading down 33 points. However, Small cap and Mid-cap stocks are in demand today. The BSE Mid Cap index is trading up 0.39% and the BSE Small Cap index is trading up 0.47%. The rupee is trading at 61.64 to the US dollar.

Indian pharma stocks are trading mixed. Dishman pharma and Torrent pharma are the leading gainers in the pack, while Ranbaxy Laboratories and Elder pharma are among the leading losers. As per the financial daily, Sun Pharmaceuticals and US based Merck have called off their three year old joint venture. Under the deal, Sun was selling Merck's anti-diabetic drug sitagliptin in India. Reportedly, the reason for the decision is still not clearly known. The said JV was aimed at bringing innovative drugs to emerging markets, including India. In April 2011, Sun Pharma and Merck had entered into deal for manufacturing and marketing of "innovative and differentiated drugs" for the markets in Asia Pacific, Latin America, Eastern Europe, the Middle East and Africa. Sun pharma being a leading pharma company was given rights to sell the said drugs. Sun pharma was trading down by 1.35% at the time of writing.

Most software stocks are trading lower today. Tech Mahindra and HCL Technologies are leading the losers. As per a leading financial daily, India's third largest software firm Wipro, has won a major outsourcing contract. The IT firm was won a multi-million dollar software contract from the American apparel maker Levi Strauss. The deal size is estimated to be about US$ 143 m. However, the deal has a variable component as well which could result in a higher payout for Wipro. The contract is for five years, commencing in the first quarter of 2015, with the possibility of an extension of 2 years. Wipro will provide IT services related to IT infrastructure management, finance, HR, customer service and customer relations. The stock was trading down 0.3% at the time of writing.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian indices continue to slide". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.